Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients

Journal article

Peer reviewed

Sayed Aliul Hasan Abdi, Shatrunajay Shukla, Jasim Khan and Abdulaziz Al Zahrani

Clinics and research in hepatology and gastroenterology, Vol.45(6), pp.101443-101443

11/2021

PMID: 32448587

Metrics

1 Record Views

Title: Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients
Creators - without role: Sayed Aliul Hasan Abdi - Jamia Hamdard
Shatrunajay Shukla - Government of India
Jasim Khan - Jamia Hamdard
Abdulaziz Al Zahrani - Al Baha University
Publication Details: Clinics and research in hepatology and gastroenterology, Vol.45(6), pp.101443-101443
Publisher: Elsevier Masson SAS
Identifiers: 9911970208331
Academic Unit: Al Baha University
Language: English
Resource Type: Journal article